Ashibio Reveals Encouraging Preclinical Data for Bone Disorders
08 Sep 2025 //
PHARMAWEB
?shibio Expand Pipeline With Vantictumab for Osteopetrosis Type 2
19 Aug 2025 //
BUSINESSWIRE
?shibio Starts Ph1b SCI Trial of Andecaliximab for HO Risk
24 Jun 2025 //
BUSINESSWIRE